China now leads the world in trials for next-gen CAR-T therapies

China is emerging as a leader in developing innovative therapies for cancer and autoimmune diseases, thanks to its large population, supportive government, and fast-track regulatory processes. These therapies, known as in vivo CAR-T-cell therapies, work by instructing the body to modify immune cells to target and destroy harmful cells. Unlike ex vivo therapies, which require lab work, in vivo therapies are more cost-effective and easier to develop. China is responsible for 82% of the global development of these therapies, with promising early trial results showing improved symptoms in patients with autoimmune diseases. The international community is taking notice, with the US recently approving a China-developed therapy for clinical trials. While the potential benefits are significant, researchers emphasize the need for more data to ensure long-term effectiveness and safety. QUESTION: How might the development of in vivo CAR-T-cell therapies in China influence global healthcare practices and treatment accessibility?